Hepatology

Top Medical News
Fatty liver more common in MAFLD than NAFLD
16 hours ago
Patients with metabolic dysfunction-associated fatty liver disease (MAFLD) see higher rates of fatty liver than those with nonalcoholic fatty liver disease (NAFLD), a recent study has found.
Yearly surveillance fails to detect cancer early in primary sclerosing cholangitis
2 days ago
In unselected patients with primary sclerosing cholangitis (PSC), yearly surveillance with carbohydrate antigen (CA) 19-9 and magnetic resonance imaging including cholangiopancreatography (MRI/MRCP) does not seem to increase the chances of detecting cancer early, a new study has found.
MEFIB bests MAST, FAST for fibrosis detection in NAFLD
4 days ago
Magnetic resonance elastography (MRE) plus FIB-4 (MEFIB) outperforms both magnetic resonance imaging [MRI]-aspartate aminotransferase (MAST) and FibroScan-AST (FAST) in detecting stage ≥2 fibrosis and at-risk nonalcoholic steatohepatitis (NASH), reveals a study.
LSM improves prediction of cholangitis outcomes
5 days ago
Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) is independently associated with primary biliary cholangitis (PBC) outcomes, a study has shown.
Married HCC patients have better overall survival
6 days ago
Among hepatocellular carcinoma (HCC) patients, being married appears to have positive prognostic implications on overall survival (OS), a recent study has found.
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
6 days ago
A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).
Plasma ammonia tied to death, hospitalization in cirrhosis patients
25 Nov 2022
Among outpatients with clinically stable cirrhosis, higher levels of plasma ammonia appear to increase the risk of mortality and liver-related complications leading to hospitalization, a recent study has found.
Special Reports
Product Highlight - Ravida
13 Sep 2022
Ravidasvir 200 mg tab
Product Highlight - OZEMPIC
16 Sep 2020
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Reducing risks and improving long-term outcomes in patients with CHB
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Conference Reports
Is vonoprazan an alternative to pantoprazole in preventing post-EVL ulcers, bleeding?
Roshini Claire Anthony, 08 Nov 2022

Vonoprazan may be as effective as pantoprazole in reducing the risk of ulcers or bleeding following endoscopic variceal ligation (EVL) in patients with portal hypertension, according to a small study from Egypt presented at the United European Gastroenterology Week (UEG 2022).

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
Roshini Claire Anthony, 11 Sep 2022

The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

Durvalumab + gemcitabine-cisplatin confers benefit in biliary tract cancer
Roshini Claire Anthony, 27 Aug 2022

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.

Is bulevirtide a potential answer for chronic hep D?
Roshini Claire Anthony, 20 Aug 2022

Bulevirtide at a dose of 2 mg or 10 mg daily induces biochemical and virological response in patients with chronic hepatitis D virus (HDV) infection, according to results of Study MYR301.

RATIONALE-208 subanalyses boost tislelizumab potential for HCC
Audrey Abella, 05 Aug 2022
The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.
Real-world studies demonstrate TAF efficacy and safety in chronic hep B
Roshini Claire Anthony, 20 Jul 2022

Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.

Unexplained hepatitis outbreak in kids: Are COVID-19, adenovirus the triggers?
Elvira Manzano, 19 Jul 2022
Cases of acute, severe hepatitis of unknown aetiology in young children have increased recently and investigations are underway, says an expert during a media briefing at ILC 2022.


Product Highlights
CME Modules